entertainment -WSS

entertainment

author：comprehensive 2025-10-02 00:42:00 - browse：6

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

WSS

Will the IRA bring competition to the biologics market?

Latest bird flu infection made farmworker sicker than earlier cases

FDA approves updated Covid vaccines

Insmed lung disease drug hits target in key Phase 3 trial

Adam's Biotech Scorecard: Do Sarepta's exon

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

Wikipedia

entertainment

hotspot

The high cost of giving birth even with insurance

Food makers to regulators: Ultra

Drug repurposing or repositioning? The language matters

Biohaven protein

Anesthesiologist group: stop taking Ozempic before surgery

Health insurers say they are turning to AI to cut costs, improve care

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Addiction doctors spar with methadone clinics over legislation

Tori Bowie and the unacceptable rates of Black maternal death

IRA could hurt research into orphan drugs for rare diseases

Wikipedia

FDA approves updated Covid vaccines

Focused ultrasound for uterine fibroids: an uphill battle

iTeos Therapeutics debuts first data on TIGIT

Average age of first period drops to 11.9 years, study shows

First Opinion Podcast: What happens when kids become caregivers?

How housing is health care on Long Island

focus

knowledge

focus

leisure time